Jeffrey T L Smith, the EVP & Chief Medical Officer of $ZYME ($ZYME), sold 11,110 shares of the company on 01-06-2025. We received data on the trade from a recent SEC ...

$ZYME insiders have traded $ZYME stock on the open market 11 times in the past 6 months. Of those trades, 6 have been purchases and 5 have been sales. Here’s a ...

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

The Zymeworks (NASDAQ:ZYME) story over the last two years was one of transformation and execution. The process started with the out-licensing of Ziihera, the brand name for zanidatamab ...

So, the natural question for Zymeworks (NASDAQ:ZYME) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at ...

Stock futures edged lower on Tuesday as investors weighed the possibility of the Fed delivering its final rate cut in 2024, with focus shifting to hints about the central bank's outlook for 2025.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research Report), Zymeworks (ZYME – Research Report) and Axsome ...